Vice President, Solid Tumor-Lung Cancer Disease Area Stronghold (Das)

Johnson & Johnson Innovative Medicines Oncology therapeutic area is recruiting for a leader of the Solid Tumor-Lung area. The strong preference is for this position to be located in Spring House, PA or Raritan, NJ, but case by case consideration will being given to other Johnson & Johnson locations and remote/flexible work arrangements.

At Johnson & Johnson Innovative Medicines, what matters most is helping people live full and healthy lives. We focus on treating, curing and preventing some of the most devastating and complex diseases of our time. And we pursue the most promising science, wherever it might be found.

Johnson & Johnson Innovative Medicines discovers and develops innovative medical solutions to address important unmet medical needs in oncology, immunology, neuroscience, infectious diseases and vaccines, and cardiovascular and metabolic diseases. Please visit http://www.JanssenRnD.com for more information.

Thriving on a diverse company culture, celebrating the uniqueness of our employees and committed to inclusion. Proud to be an equal opportunity employer.

Johnson & Johnson Innovative Medicines Oncology Therapeutic Area is committed to a singular vision: to transform cancer to a preventable, chronic or curable disease by delivering extraordinary and accessible diagnostic and therapeutic solutions that prolong and improve patients' lives.

The VP, Solid Tumors-Lung DAS, will oversee a multidisciplinary team to advance the scientific strategy and business plan for the discovery and development of lung cancer therapeutics. This team will be responsible for determining the strategy for drug discovery and development in lung cancer across the Johnson & Johnson pipeline and executing on a business plan with clear deliverables and resource needs. The position requires close collaboration with functional areas (including Discovery, Translational Research/Diagnostics, Clinical Development) as well as key stakeholders outside Oncology R&D. Included in the strategy will be a determination of the priorities and approach to leveraging external opportunities from both academia and industry.

ESSENTIAL FUNCTIONS:

• Lead the strategy and operational activities to deliver a portfolio of programs that aim to improve the life of patients with lung cancer.

• Guide the discovery and early development of New Molecular Entities, including novel target identification, translational research and, the continual application of innovative approaches towards treating lung cancer.

• Work closely functional partners (Translational, CMC, Clinical, Regulatory) to ensure an integrated and strategic approach to flawless execution and systematic oversight of lung cancer programs.

• Champion external opportunities to accelerate/broaden the overall DAS strategy by working in close partnership with Business Development and the Innovation Center network.

• Build and foster cross-sector and Cross-DAS collaboration with key stakeholders to advance novel drug strategies.

• Work closely with DAS Leaders, compound development teams, and Janssen Oncology senior leadership to align on portfolio priorities and identify resource needs for priority program execution.

• Interact with clinical investigators and Key Opinion Leaders and oversee scientific advisory boards as appropriate to execute strategy.